Relative risk* of six site-specific cancers in patients with SpA treated with TNFi (n=8703)† versus TNFi-naïve Swedish patients with SpA (n=28 164)† and Swedish general population comparator subjects (n=131 687)† 2001 to 2011
| TNFi-treated (DANBIO and ARTIS) patients with SpA versus TNFi-naïve | TNFi-treated (DANBIO and ARTIS) patients with SpA versus the general population | TNFi-naïve patients with SpA versus the general population | ||||
|---|---|---|---|---|---|---|
| Cancer site | N cancers TNFi-treated/TNFi-naïve | RR (95% CI) | N cancers TNFi-treated/general population | RR (95% CI) | N cancers TNFi naïve/general population | RR (95% CI) |
| Prostate | 23/296 | 0.5 (0.3 to 0.8) | 23/1125 | 0.6 (0.4 to 0.9) | 296/1125 | 1.2 (1.1 to 1.4) |
| Lung | 7/76 | 0.6 (0.3 to 1.3) | 7/357 | 0.6 (0.3 to 1.2) | 76/357 | 1.0 (0.7 to 1.2) |
| Colorectal | 11/86 | 1.0 (0.5 to 2.0) | 11/580 | 0.7 (0.4 to 1.2) | 86/580 | 0.7 (0.5 to 0.8) |
| Malignant lymphoma | 9/54 | 0.8 (0.4 to 1.8) | 9/258 | 0.8 (0.4 to 1.7) | 54/258 | 1.0 (0.7 to 1.3) |
| Breast | 30/179 | 1.3 (0.9 to 2.0) | 30/837 | 1.3 (0.9 to 1.9) | 179/837 | 1.0 (0.8 to 1.2) |
| Malignant melanoma | 13/57 | 1.4 (0.7 to 2.6) | 13/275 | 1.3 (0.7 to 2.3) | 57/275 | 1.0 (0.7 to 1.3) |
*Age-standardised and sex-standardised incidence ratio (RR) with 95% CIs.
†DANBIO and ARTIS=TNFi-treated SpA, persons-years=33 908, Swedish TNFi-naïve patients with SpA, person-years=182 136, Swedish general population comparator subjects person-years=862 380.
ARTIS, Anti-Rheumatic Therapy in Sweden; DANBIO, Danish biologics register; RR, relative risk; SpA, spondyloarthritis; TNFi, tumour necrosis factor inhibitor.